Efficacy of a multiplex paclitaxel emission stent using a Pluronic® mixture membrane versus a covered metal stent in malignant biliary obstruction: A prospective randomized comparative study

Sung Ill Jang, Se Joon Lee, Seok Jeong, Don Haeng Lee, Myung Hwan Kim, Hong Jin Yoon, Dong Ki Lee

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background/Aims: A drug-eluting stent for unresectable malignant biliary obstruction was developed to increase stent patency by preventing tumor ingrowth. The safety and efficacy of a new generation of metallic stents covered with a paclitaxel-incorporated membrane using a Pluronic® mixture (MSCPM-II) were compared prospectively with those of covered metal stents (CMSs) in patients with malignant biliary obstructions. Methods: This study was initially designed as a prospective randomized trial but was closed early because of a high incidence of early occlusion. Therefore, the data were analyzed using the intent-to-treat method. A total of 72 patients with unresectable distal malignant biliary obstructions were prospectively enrolled. Results: The two groups did not differ significantly in basic characteristics and mean followup period (MSCPM-II 194 days vs CMS 277 days, p=0.063). Stent occlusion occurred in 14 patients (35%) who received MSCPM-II and in seven patients (21.9%) who received CMSs. Stent patency and survival time did not significantly differ between the two groups (p=0.355 and p=0.570). The complications were mild and resolved by conservative management in both groups. Conclusions: There were no significant differences in stent patency or patient survival in MSCPM-II and CMS patients with malignant biliary obstructions.

Original languageEnglish
Pages (from-to)567-573
Number of pages7
JournalGut and liver
Volume11
Issue number4
DOIs
Publication statusPublished - 2017 Jul

Fingerprint

Poloxamer
Paclitaxel
Stents
Metals
Membranes
Drug-Eluting Stents
Survival
Safety

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{dd81f74c2910438995c5dab832de45cf,
title = "Efficacy of a multiplex paclitaxel emission stent using a Pluronic{\circledR} mixture membrane versus a covered metal stent in malignant biliary obstruction: A prospective randomized comparative study",
abstract = "Background/Aims: A drug-eluting stent for unresectable malignant biliary obstruction was developed to increase stent patency by preventing tumor ingrowth. The safety and efficacy of a new generation of metallic stents covered with a paclitaxel-incorporated membrane using a Pluronic{\circledR} mixture (MSCPM-II) were compared prospectively with those of covered metal stents (CMSs) in patients with malignant biliary obstructions. Methods: This study was initially designed as a prospective randomized trial but was closed early because of a high incidence of early occlusion. Therefore, the data were analyzed using the intent-to-treat method. A total of 72 patients with unresectable distal malignant biliary obstructions were prospectively enrolled. Results: The two groups did not differ significantly in basic characteristics and mean followup period (MSCPM-II 194 days vs CMS 277 days, p=0.063). Stent occlusion occurred in 14 patients (35{\%}) who received MSCPM-II and in seven patients (21.9{\%}) who received CMSs. Stent patency and survival time did not significantly differ between the two groups (p=0.355 and p=0.570). The complications were mild and resolved by conservative management in both groups. Conclusions: There were no significant differences in stent patency or patient survival in MSCPM-II and CMS patients with malignant biliary obstructions.",
author = "Jang, {Sung Ill} and Lee, {Se Joon} and Seok Jeong and Lee, {Don Haeng} and Kim, {Myung Hwan} and Yoon, {Hong Jin} and Lee, {Dong Ki}",
year = "2017",
month = "7",
doi = "10.5009/gnl16428",
language = "English",
volume = "11",
pages = "567--573",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "4",

}

Efficacy of a multiplex paclitaxel emission stent using a Pluronic® mixture membrane versus a covered metal stent in malignant biliary obstruction : A prospective randomized comparative study. / Jang, Sung Ill; Lee, Se Joon; Jeong, Seok; Lee, Don Haeng; Kim, Myung Hwan; Yoon, Hong Jin; Lee, Dong Ki.

In: Gut and liver, Vol. 11, No. 4, 07.2017, p. 567-573.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of a multiplex paclitaxel emission stent using a Pluronic® mixture membrane versus a covered metal stent in malignant biliary obstruction

T2 - A prospective randomized comparative study

AU - Jang, Sung Ill

AU - Lee, Se Joon

AU - Jeong, Seok

AU - Lee, Don Haeng

AU - Kim, Myung Hwan

AU - Yoon, Hong Jin

AU - Lee, Dong Ki

PY - 2017/7

Y1 - 2017/7

N2 - Background/Aims: A drug-eluting stent for unresectable malignant biliary obstruction was developed to increase stent patency by preventing tumor ingrowth. The safety and efficacy of a new generation of metallic stents covered with a paclitaxel-incorporated membrane using a Pluronic® mixture (MSCPM-II) were compared prospectively with those of covered metal stents (CMSs) in patients with malignant biliary obstructions. Methods: This study was initially designed as a prospective randomized trial but was closed early because of a high incidence of early occlusion. Therefore, the data were analyzed using the intent-to-treat method. A total of 72 patients with unresectable distal malignant biliary obstructions were prospectively enrolled. Results: The two groups did not differ significantly in basic characteristics and mean followup period (MSCPM-II 194 days vs CMS 277 days, p=0.063). Stent occlusion occurred in 14 patients (35%) who received MSCPM-II and in seven patients (21.9%) who received CMSs. Stent patency and survival time did not significantly differ between the two groups (p=0.355 and p=0.570). The complications were mild and resolved by conservative management in both groups. Conclusions: There were no significant differences in stent patency or patient survival in MSCPM-II and CMS patients with malignant biliary obstructions.

AB - Background/Aims: A drug-eluting stent for unresectable malignant biliary obstruction was developed to increase stent patency by preventing tumor ingrowth. The safety and efficacy of a new generation of metallic stents covered with a paclitaxel-incorporated membrane using a Pluronic® mixture (MSCPM-II) were compared prospectively with those of covered metal stents (CMSs) in patients with malignant biliary obstructions. Methods: This study was initially designed as a prospective randomized trial but was closed early because of a high incidence of early occlusion. Therefore, the data were analyzed using the intent-to-treat method. A total of 72 patients with unresectable distal malignant biliary obstructions were prospectively enrolled. Results: The two groups did not differ significantly in basic characteristics and mean followup period (MSCPM-II 194 days vs CMS 277 days, p=0.063). Stent occlusion occurred in 14 patients (35%) who received MSCPM-II and in seven patients (21.9%) who received CMSs. Stent patency and survival time did not significantly differ between the two groups (p=0.355 and p=0.570). The complications were mild and resolved by conservative management in both groups. Conclusions: There were no significant differences in stent patency or patient survival in MSCPM-II and CMS patients with malignant biliary obstructions.

UR - http://www.scopus.com/inward/record.url?scp=85021837067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021837067&partnerID=8YFLogxK

U2 - 10.5009/gnl16428

DO - 10.5009/gnl16428

M3 - Article

C2 - 28335102

AN - SCOPUS:85021837067

VL - 11

SP - 567

EP - 573

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 4

ER -